Publication | Open Access

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

HepatologyMedicineRandomised Phase 3Clinical TrialsPathologyLenvatinib Versus SorafenibPharmacotherapyNon-inferiority TrialLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaHealth Sciences